deferitrin

Known as: 4-Hydroxydesazadesferrithiocin 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2010
01220052010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
The current solution to iron-mediated damage in transfusional iron overload disorders is decorporation of excess unmanaged metal… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2008
2008
A series of iron-clearing efficiencies (ICEs), ferrokinetics, and toxicity studies for ( S)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4… (More)
Is this relevant?
2007
2007
Deferitrin (GT-56-252) is the first drug in a class of desferrithiocin-derived hexadentate iron chelators. Genzyme Corp is… (More)
Is this relevant?
Review
2007
Review
2007
Deferitrin (GT-56-252) is the first drug in a class of desferrithiocin-derived hexadentate iron chelators. Genzyme Corp is… (More)
Is this relevant?
2006
2006
Iron chelation therapy using deferoxamine or deferiprone (L1) is effective for the treatment of most transfused iron-loaded… (More)
Is this relevant?
Review
2006
Review
2006
Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia… (More)
Is this relevant?
Review
2005
Review
2005
Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic… (More)
Is this relevant?
Review
2005
Review
2005
Effective new therapies and mechanisms have been developed for the targeting and prevention of iron overload and toxicity in… (More)
Is this relevant?